PosiFunda · Fundamentals

Eupraxia Pharmaceuticals Inc.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (5)

Eupraxia Pharmaceuticals Inc. made a loss over the last year.

Compared with Healthcare companies in Canada.

P/E ratio

Loss

Eupraxia Pharmaceuticals Inc. made a loss over the last year, so its P/E ratio is not meaningful.

P/B ratio

3.58

The share price is 3.58 times Eupraxia Pharmaceuticals Inc.'s book value per share, higher than 64% of Healthcare companies in Canada.

Market cap

C$659 M

The total market value of all of Eupraxia Pharmaceuticals Inc.'s shares at today's price (share price × number of shares), larger than 92% of Healthcare companies in Canada. PosiCap size class: Mini Cap.

Return on equity (ROE)

-66.7%

Eupraxia Pharmaceuticals Inc. lost 66.7% of its shareholders' money over the last year, lower than 68% of Healthcare companies in Canada.

Dividend yield

None

Eupraxia Pharmaceuticals Inc. does not currently pay a dividend.

Questions

What is Eupraxia Pharmaceuticals Inc.'s return on equity?

Eupraxia Pharmaceuticals Inc. lost 66.7% of its shareholders' money over the last year, lower than 68% of Healthcare companies in Canada.

Does Eupraxia Pharmaceuticals Inc. pay a dividend?

No. Eupraxia Pharmaceuticals Inc. does not currently pay a dividend.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.